Medunik presents FDA-approved hydroxyurea-based treatment for infants
Siklos® is the first and only FDA-approved hydroxyurea-based treatment indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in paediatric patients two years of age and older with sickle cell anaemia with recurrent moderate to severe painful crises. The importance of optimal dosing of hydroxyurea in sickle cell…